Audit a URL →

Sign in Sign up free

Loading…

Weekly · Sunday Morning

Five longevity claims.
Worth your time.
Every Sunday.

Last Sunday

Rapamycin extends mouse lifespan 9–14%
NAD+ precursors reverse aging in humans
Blue-light glasses improve sleep quality
Walking 10 min after meals blunts glucose
Verdict change — caffeine half-life downgraded

5 audits·1 verdict change·0 affiliate links·Every Sunday

Joining 1,247 readers — founders, MDs, and longevity-obsessed people who fact-check their own health decisions.

Browse

Decisions Claims Content Creators

Product

Audit a URL Sunday roundup API (soon)Pricing

About

FAQ Methodology Editorial Standards Corrections Press & brand RSS feed

Legal

Terms of Service Privacy Policy DMCA

Finally, something serious in this space.
Because we actually read the papers.

© 2026 Whalespan. Independent, evidence-graded longevity.

Essentials: Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson — Whalespan

Content›Video›Essentials: Psychedelics for…

Essentials: Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson

Andrew Huberman35m · 2025-07-24

Claims Made

63

Claims Supported

45

Support Rate

71%

Support rate

45 of 63 claims supported

45 supported18 partial / not

Claims from this content

48

✓Well SupportedPsychedelics like LSD and psilocybin augment serotonin and have shown impressive results in clinical trials for relieving major depression.✕Not SupportedThere is no evidence that microdosing psilocybin increases creativity, enhances cognition, or provides sustained mood improvement.◐Partially SupportedClinical studies on psilocybin for depression typically use dosages ranging from 0mg to 30mg.◐Partially SupportedIntense psychedelic experiences can include sensations of dying or extreme cardiovascular events like a racing heart.Well Supported

More from Andrew Huberman

Andrew Huberman on Creatine

Huberman X thread: creatine and aging

Andrew Huberman on Morning Sunlight

Discussion

Native comments, Twitter mentions, and Reddit threads about this content — surfaced together so the conversation isn't fragmented across platforms.

M

Share your read of this content…

Posting publicly as you · linked to your social profiles

Sort by:

AV

A. Volkovreader

4h

Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.

NP

N. Park

2d

Would love a "what would change this verdict" RSS feed. Sign me up if it exists.

✓

Psychedelics may promote neuroplasticity, potentially contributing to improved outcomes in psychiatric treatments and repair of brain injury from repetitive head impacts.

✓Well SupportedApproximately one-third of individuals may experience a 'bad trip' during a 30mg psilocybin experience.

◐Partially SupportedPsychedelic experiences can lead to a realization of personal agency and empowerment.

◐Partially SupportedMDMA leads to robust increases in dopamine and serotonin.

◐Partially SupportedResearch is planned to investigate if psychedelics can help retired UFC athletes with depression from head impacts, and improve cognitive function and gray matter volume.

◐Partially SupportedHigh doses of psychedelics may produce improvements in depression and addiction lasting months to over a year.

◐Partially SupportedClassical psychedelics primarily act on the serotonin 2a receptor, while ketamine acts on the NMDA receptor.

◐Partially SupportedPaul Stamets' specific microdosing protocols have not been scientifically studied.

◐Partially SupportedSerotonin generally promotes a state of contentment within the immediate experience, while the dopamine system drives an external focus on the world and possibilities.

✕Not SupportedStudies on microdosing psilocybin have found no effect or slight impairment in time estimation and production tasks.

◐Partially SupportedMicrodosing psilocybin may function as a better alternative to SSRIs like Prozac for antidepressant effects.

◐Partially SupportedSurrendering to a psychedelic experience, rather than resisting it, is crucial for avoiding a bad trip.

◐Partially SupportedPsychedelics are being explored for the potential treatment and reversal of neurological injuries.

◐Partially SupportedA therapeutic model for psilocybin use involves preparation where the person feels comfortable with their guides, and allowing all emotional responses.

◐Partially SupportedPsychedelics can be understood as dissolving predictive models of the world.

◐Partially SupportedMDMA is classified as an empathogen or entactogen, not a psychedelic drug.

◐Partially SupportedPsychedelic experiences can lead to persisting changes in self-representation.

◐Partially SupportedDifferences in serotonin receptor subtypes lead to profoundly different subjective outcomes.

◐Partially SupportedMDMA may be better for treating trauma than classic psychedelics due to a lower chance of inducing a challenging experience.

◐Partially SupportedSerotonin itself is not psychedelic.

◐Partially SupportedTherapeutic responses in psychedelic studies are often diminished when participants are in an fMRI or engaged in extensive cognitive tasks.

◐Partially SupportedPsychedelic research studies have been conducted for smoking cessation.

◐Partially SupportedClinical trials for psychedelics at Johns Hopkins have included studies for healthy individuals, not just those with diagnosable disorders.

◐Partially SupportedEven healthy individuals may experience underlying issues surfacing when administered psychedelics in a therapeutic model.

◐Partially SupportedPsychedelic experiences can alter the models individuals hold of reality, including the sense of self.

◐Partially SupportedSomatic and perceptual experiences can reshape neural circuitry and lead to lasting changes in self-perception.

◐Partially SupportedPsychedelic experiences can lead to lasting changes in identity and neural circuitry.

◐Partially SupportedPsychedelic trial participation requires screening for psychotic disorders, bipolar disorder, and cardiovascular conditions.

◐Partially SupportedThe perception of self can be reshaped by psychedelic experiences facilitated by serotonergic agents and therapists.

◐Partially SupportedPreparation for psychedelic trials includes developing a therapeutic rapport and explaining potential experiences.

◐Partially SupportedAugmenting extracellular serotonin may lead to a reduction in depressive symptoms.

◐Partially SupportedPsychedelic experiences can range from the most beautiful to the most terrifying, emphasizing the importance of managing expectations and preparation.

◐Partially SupportedEngaging with intense experiences in an undeterred manner during psychedelic therapy allows individuals to integrate insights into their reality.

◐Partially SupportedPsychedelics should ideally be undertaken within a safe, supportive environment.

◐Partially SupportedChallenging psychedelic experiences can lead to transcendental experiences linked to positive long-term outcomes.

◐Partially SupportedPsychedelics can induce a state of dishabituation, which is therapeutically useful for expanding perceptual bubbles.

◐Partially SupportedA therapeutic goal of psychedelics is to expand a restricted perceptual bubble, with safety protocols allowing exploration without undue worry.

◐Partially SupportedPsychedelics could potentially aid recovery from stroke and related disorders.

◐Partially SupportedPsychedelic experiences can lead to identity level changes in individuals with depression, anxiety, or those trying to quit smoking.

◐Partially SupportedPsychedelic experiences can involve an expansion of narrow perception related to sound, emotion, history, or fear of the future.

✕Not SupportedIntense focus on mundane tasks during a psychedelic experience can be disorienting.

◐Partially SupportedPsychedelics like MDMA and psilocybin can enable individuals to reprocess trauma through memory reconsolidation.

◐Partially SupportedPsychedelic compounds have shown success in alleviating depression and treating trauma.

◐Partially SupportedIndividuals with severe psychiatric illnesses like schizophrenia or mania are at higher risk of adverse effects from psychedelics compared to those with depression or anxiety.